MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijpx.2026.100587

Медицинская библиотека · International journal of pharmaceutics: X · 2026

Triptolide loaded cerium oxide nanozyme based oral nanoplatform for targeted colitis therapy.

Lu Jing, Chen Yiming, Ding Wenxing, Zheng Shuhui, Yang Liping, Wang Yiting, Ji Qingdong, Qi Chendong, Gao Feng

СтатьяПеревод пока не подготовлен

Аннотация

Ulcerative colitis (UC) is a type of colonic inflammation characterized by immune dysregulation and intestinal inflammation. Cerium oxide (CeO₂) nanozyme can effectively downregulate reactive oxygen species (ROS), but it lacks anti-inflammatory and other pharmacological activities. Triptolide (TP) has anti-inflammatory, antioxidant, antifibrotic, and autophagy-regulating pharmacological properties. However, severe gastrointestinal side effects hinder its clinical application. Therefore, this study aimed to develop TP-loaded CeO₂ nanozymes (T-C). T-C effectively reduces ROS at sites of colitis. In addition, chitosan, chondroitin sulfate, and pectin were employed as carriers to construct T-C-loaded nanoparticles (T-C@pNP), in which chitosan promoted nanoparticle assembly, chondroitin sulphate enhances uptake of nanoparticle, and pectin enabled pectinase-responsive release, resulting in a novel oral nanoplatform for colitis treatment. In a mouse colitis model, T-C@pNP significantly alleviated inflammation-induced weight loss, colon shortening, and colon damage, demonstrating notable therapeutic effects. T-C@pNP not only downregulated ROS, but also reduced the levels of proinflammatory factors (TNF-α, IL-6, and IFN-γ), possibly through inhibition of the nuclear factor kappa-B (NF-κB) pathway, and diminished neutrophil infiltration. Furthermore, it regulated macrophage polarization, potentially alleviated inflammation-associated fibrosis, and disrupted the vicious cycle of inflammation. Moreover, T-C@pNP may activate epithelial cell autophagy, enhance the intestinal mucus barrier, promote the expression of ZO-1 and occludin, and partially modulate the gut microbiota composition, thereby improving intestinal barrier repair. In conclusion, complemented by satisfactory anti-inflammatory and biosafety results, this nanoplatform represents a promising treatment option for colitis in rats.

Для цитирования: Lu Jing, Chen Yiming, Ding Wenxing, Zheng Shuhui, Yang Liping, Wang Yiting, Ji Qingdong, Qi Chendong, Gao Feng. Triptolide loaded cerium oxide nanozyme based oral nanoplatform for targeted colitis therapy.. International journal of pharmaceutics: X. 2026. DOI: 10.1016/j.ijpx.2026.100587.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.